| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 9 Jul 2026 | 3 Jul 2026 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/07/2026 inter alia to consider and approve 1. The proposal for raising funds by way of a Rights Issue of equity shares to the eligible equity shareholders of the Company for an aggregate amount of up to ?500000000 (Rupees Fifty Crores Only) in accordance with the applicable provisions of the Companies Act 2013 the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 the SEBI (LODR) Regulations 2015 and other applicable laws. 2. The proposal for increase in the Authorised Share Capital of the Company. 3. Consequent alteration of the Capital Clause of the Memorandum of Association of the Company. 4. To determine and approve the detailed terms and conditions of the Rights Issue including but not limited to the issue size rights entitlement ratio issue price record date rights issue schedule appointment of intermediaries draft Letter of Offer and such other matters incidental or connected therewith. 5. Discussion on Appointment and Resignation of Directors. Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As per BSE Announcement dated on: 09.07.2026) | ||
| Board Meeting | 26 Jun 2026 | 23 Jun 2026 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/06/2026 inter alia to consider and approve As per Attachment As per Attached outcome of meeting (As Per BSE Announcement Dated on: 26/06/2026) | ||
| Board Meeting | 22 May 2026 | 11 May 2026 |
| Audited Results Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve Intimation of Board Meeting to be held on 22nd May 2026 for the quarter and year ended 31st March 2026 Outcome of Board Meeting for Audited Results for 31st March, 2026 (As Per BSE Announcement Dated on:22.05.2026) | ||
| Board Meeting | 13 Feb 2026 | 5 Feb 2026 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve 1. Approval of unaudited Financial Results of the Company for the quarter ended 31st December 2025; 2. Any other business with the permission of Chairperson. Outcome of Board Meeting held on 13th February, 2026. Revised Un-audited Financial Result for 31st December, 2025. (As per BSE Announcement dated on: 13.02.2026) | ||
| Board Meeting | 13 Nov 2025 | 5 Nov 2025 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve 1. Unaudited Financial Results of the Company for the Half yearly and quarter ended 30th September 2025; 2. Any other business with the permission of Chairperson. Outcome of Board Meeting Held on 13th November, 2025 (As Per BSE Announcement Dated on: 13/11/2025) | ||
| Board Meeting | 5 Sep 2025 | 2 Sep 2025 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/09/2025 inter alia to consider and approve To discuss and approve the following matters: Discussion on Notice for 38th Annual General Meeting for the Company. Discussion on Director Report of the Company for the Financial Year 2024-2025. Discussion to Fix Date Place and Timing of 38th Annual General Meeting of the Company Discussion on matter related to Loan to Equity shares of the Company. Any other business with the permission of Chairperson. Outcome of Board Meeting held on 05th September, 2025 (As per BSE Announcement Dated on 05.09.2025) | ||
| Board Meeting | 25 Aug 2025 | 19 Aug 2025 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/08/2025 inter alia to consider and approve 1. Discussion on Appointment of M/s Sarang Shivajirao Chavan& Associate as a Statutory Auditor of the Company; 2. Discussion on Appointment of New Director. 3. Any other business with the permission of Chairperson. Outcome of Board meeting for Appointment Statutory Auditor and Independent Director (As Per BSE Announcement Dated on: 26/08/2025) Revised outcome of Board Meeting held on 25th August 2025. The earlier revised outcome uploaded has incorrect w.e.f date of appointment of statutory auditor. The correct w.e.f date is 25th August,2025 (As per BSE Announcement Dated on 27/08/2025) | ||
| Board Meeting | 12 Aug 2025 | 5 Aug 2025 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve Intimation of Board Meeting to be held on 12th August 2025. Approval of unaudited financial results for the quarter ended 30/06/2025 Approval of unaudited financial results for the quarter ended 30th June 2025 (As Per BSE Announcement Dated on:12.08.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
